【据《Ophthalmology》2023年5月报道 】题 :NOV03治疗睑板腺功能障碍相关干眼:GOBI随机3期研究结果( 美国Tauber眼科中心 作者 Joseph Tauber 等)。 睑板腺功能障碍(meibomian gland dysfunction,MGD)是蒸发过强型干眼(dry eye disease,DED)的主要原因。由于脂质层质或量异常引起泪液蒸发增加,导致泪液高渗和眼表炎症的...
1、Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease 2、Novaliq Announces Positive Topline Results for Its CyclASol® Phase 2B/3 Essence Trial in Patients with Dry Eye Disease...
Purpose : To assess the efficacy and safety of NOV03 (100% perfluorohexyloctane; F6H8) an investigational, novel, water-free, preservative-free sterile eye drop dosed four times a day (QID) compared to hypotonic saline eye drops for the treatment of the signs and symptoms of dry eye ...
NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2023 May;130(5):516-524(NOV03治疗伴睑板腺功能障碍的干眼症:随机3期GOBI研究的结果。《眼科学》。2023年5月;130(5):516-524) Sheppard JD, Kurata F, Epitropoulos ...
"Bausch + Lomb, our global eye health business, is focused on researching and bringing forward new options for unmet medical needs, including Dry Eye Disease associated with MGD. It's estimated that more than 16 million Americans suffer from Dry Eye Disease3, and if approved, NOV03 ...
Tauber J, Berdy GJ, Wirta DL, Krösser S, Vittitow JL; GOBI Study Group. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. Ophthalmology. 2023 May;130(5):516-524(NOV03治疗伴睑板腺功能障碍的干眼症:随机3期GOBI研究的结果。
NOV03 shows positive phase 2 results for evaporative dry eyeForand, Rebecca L.Ocular Surgery News
【据《Ophthalmology》2023年5月报道 】题 :NOV03治疗睑板腺功能障碍相关干眼:GOBI随机3期研究结果( 美国Tauber眼科中心 作者 Joseph Tauber 等)。 睑板腺功能障碍(meibomian gland dysfunction,MGD)是蒸发过强型干眼(dry eye disease,DED)的主要原因。由于脂质层质或量异常引起泪液蒸发增加,导致泪液高渗和眼表炎症的...
Purpose: NOV03 has a unique dual mode of action to address dry eye disease (DED) associated with meibomian gland dysfunction. SEECASE evaluated the efficacy, safety, and tolerability of NOV03 at 2 dosing regimens compared with a saline comparator in patients with DED. Methods: SEECASE was a...